temozolomide has been researched along with Hemorrhagic Disorders in 1 studies
Hemorrhagic Disorders: Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 7.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 3.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kopecký, J | 1 |
| Priester, P | 1 |
| Slovácek, L | 1 |
| Petera, J | 1 |
| Kopecký, O | 1 |
| Macingova, Z | 1 |
1 other study available for temozolomide and Hemorrhagic Disorders
| Article | Year |
|---|---|
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |